Sutro Biopharma amends Tasly license for STRO-002; gets $25M initial, up to $350M in milestones

SUTRO BIOPHARMA, INC.

Amendment to Tasly license for STRO-002 in Greater China (China, HK, Macau, Taiwan).
Initial payment revised to $25M; $15M escrow in Q2 2022 payable on regulatory milestones.
Additional potential milestone payments up to $350M for development, regulatory, commercialization.
Tasly retains exclusive rights to develop and commercialize STRO-002 in the region.
Amendment effective April 18, 2022; full terms to be filed in Q2 2022 10-Q.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.